V-Square Quantitative Management’s Cytokinetics CYTK Stock Holding History

V-Square Quantitative Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7K	Buy	+267	New	+$19.2K	﹤0.01%	701

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

V-Square Quantitative Management's CYTK Position: Q2 2026 in Review

V-Square Quantitative Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 267 shares worth $22.7K. The stake represents ﹤0.01% of the portfolio and ranks #701 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

V-Square Quantitative Management held 267 shares of Cytokinetics worth $22.7K as of Q2 2026.
Cytokinetics was a new V-Square Quantitative Management position in Q2 2026.
Cytokinetics made up ﹤0.01% of V-Square Quantitative Management's portfolio in Q2 2026, its #701 holding.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on V-Square Quantitative Management's 13F filing for Q2 2026, filed 27 Jul 2026.